A phase I, extended release formulations trial of ACH-4471 in healthy volunteers.

Trial Profile

A phase I, extended release formulations trial of ACH-4471 in healthy volunteers.

Planning
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2017

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Glomerulonephritis; Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 07 Nov 2017 New trial record
    • 02 Nov 2017 According to Achillion media release, company plans to initiate the trial by the end of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top